Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab biosimilar (NeuClone Pharmaceuticals)
- Development stage
- Preclinical
- Lead developer
- NeuClone
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
NeuClone Pharmaceuticals is developing an adalimumab biosimilar that references the originator biologic Humira. Adalimumab is a recombinant human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor-alpha (TNF-alpha) and neutralizes its biological activity by blocking its interaction with the p55 and p75 cell surface TNF receptors. This biosimilar candidate is being developed in partnership with the Serum Institute of India for the treatment of various autoimmune and inflammatory disorders, including rheumatoid arthritis, plaque psoriasis, Crohn's disease, ankylosing spondylitis, and ulcerative colitis. As of recent pipeline updates, the program is in late preclinical development, utilizing NeuClone's proprietary NeuMAX platform for high-quality biosimilar production.
- Other names
- adalimumab biosimilarHumira biosimilar
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on adalimumab biosimilar (NeuClone Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab biosimilar (NeuClone Pharmaceuticals).